Tasca Therapeutics: Drug Discovery Platform Secures $52 Million (Series A)
By Amit Chowdhry ● Dec 13, 2024
Tasca Therapeutics, a biotechnology company that utilizes a unique drug discovery platform that identifies and maps novel lipid-binding pockets on proteins to develop new medicines to treat human diseases, announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation from Invus Group. This funding round will advance Tasca’s novel drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and expand its drug candidate pipeline.